Drugs /

amg 176

Back to Drugs List

Overview

NCI Definition [1]:
An inhibitor of induced myeloid leukemia cell differentiation protein MCL-1 (myeloid cell leukemia-1), with potential pro-apoptotic and antineoplastic activities. Upon administration, AMG 176 binds to and inhibits the activity of MCL-1. This disrupts the formation of MCL-1/Bcl-2-like protein 11 (BCL2L11; BIM) complexes and induces apoptosis in tumor cells. MCL-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.

Clinical Trials

View Clinical Trials for amg 176

Amg 176 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating amg 176, 1 is phase 1 (1 open).

PML-RARA Fusion, t(15;17)(q22;q12), and t(15;17)(q24;q21) are the most frequent biomarker inclusion criteria for amg 176 clinical trials.

Acute myeloid leukemia and multiple myeloma are the most common diseases being investigated in amg 176 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Amg 176
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating amg 176 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
mcl-1 inhibitor amg 176
Drug Target(s) [2]:
MCL1
NCIT ID [1]:
C127817

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.